1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of thetransaction
|
Cash payout of £270,644.71 less applicable tax withholding in
respect of 6,700.785 notional ADS following vesting of an award
made on 2 March 2015 under the GlaxoSmithKline Deferred Investment
Award plan.
|
|
c)
|
Price(s) and
volume(s)
|
Volume(s)
|
|
$40.39
|
6,700.785
|
||
d)
|
Aggregated
information
|
n/a (single transaction)
|
|
Aggregated volumePrice
|
|
||
e)
|
Date
of the transaction
|
2019-03-04
|
|
f)
|
Place of the
transaction
|
n/a
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
05, 2019
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|